The ongoing FLAURA (NCT02296125), a randomized, double-blind phase III trial to assess the efficacy and safety of osimertinib versus erlotinib/gefitinib as first-line therapy in EGFR mutated locally advance NSCLC are much awaited to position osimertinib as frontline therapy [101]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.